{"id":{"repo_id":"glasgow","oai_identifier":"oai:theses.gla.ac.uk:4271"},"canonical_url":"https://search.ndltd.org/etd/glasgow/oai:theses.gla.ac.uk:4271","repository":{"repo_id":"glasgow","name":"University of Glasgow","base_url":"https://theses.gla.ac.uk/cgi/oai2"},"display":{"title":"Investigation of autophagy as a survival factor for chronic myeloid leukaemia","abstract":"Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukemia (CML), however, fail to cure the disease due to the persistence of a refractory fraction of stem/progenitor cells. Autophagy is a recycling mechanism utilised by the cell as a survival mechanism under stressful conditions, and its induction has been suggested to have a cytoprotective role in cancer cells. In this study we demonstrate that autophagy is triggered in CML upon TKI-mediated inhibition of BCR-ABL, and protects from cell death. In order to evaluate if specific autophagy inhibition enhances TKI effects, we stably transduced primary CML stem/progenitor cells with a vector carrying a short-hairpin against the key autophagy gene ATG7. Knock-down of basal ATG7/autophagy levels in CML stem/progenitor cells inhibited by approximately 50% the survival of the cells in a clonogenic assay, and reduced by 75% their erythroid differentiation potential. Furthermore, ATG7 knock-down enhanced the effects of TKIs imatinib (IM; 1st), dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without TKI treatment, did not have a significant effect on survival and proliferation. ATG7 was also knocked-down in final disease stage, blast crisis (BC), patient-derived K562 and KCL22 cell lines. Both cell lines appeared to depend significantly on autophagy for survival as indicated by high apoptosis levels (70-100%) after ATG7 knock-down. Interestingly, ATG7 knock-down cells appeared to be more differentiated compared to the control (scrambled shRNA). Our findings suggest a role for basal autophagy in the survival, differentiation decisions and clonogenicity of CML cells, and support the combined use of autophagy inhibition with TKIs for the eradication of CML stem/progenitor cells. This could be partially attributed to a bypass of the differentiation block upon autophagy inhibition, which facilitates TKI-targeting. We underline the necessity for the development of specific autophagy inhibitors that in combination with TKIs could potentially eradicate the fraction of persistent CML stem/progenitor cells and offer a curative option for CML patients.","abstract_html":"Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukemia (CML), however, fail to cure the disease due to the persistence of a refractory fraction of stem/progenitor cells. Autophagy is a recycling mechanism utilised by the cell as a survival mechanism under stressful conditions, and its induction has been suggested to have a cytoprotective role in cancer cells. In this study we demonstrate that autophagy is triggered in CML upon TKI-mediated inhibition of BCR-ABL, and protects from cell death. In order to evaluate if specific autophagy inhibition enhances TKI effects, we stably transduced primary CML stem/progenitor cells with a vector carrying a short-hairpin against the key autophagy gene ATG7. Knock-down of basal ATG7/autophagy levels in CML stem/progenitor cells inhibited by approximately 50% the survival of the cells in a clonogenic assay, and reduced by 75% their erythroid differentiation potential. Furthermore, ATG7 knock-down enhanced the effects of TKIs imatinib (IM; 1st), dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without TKI treatment, did not have a significant effect on survival and proliferation. ATG7 was also knocked-down in final disease stage, blast crisis (BC), patient-derived K562 and KCL22 cell lines. Both cell lines appeared to depend significantly on autophagy for survival as indicated by high apoptosis levels (70-100%) after ATG7 knock-down. Interestingly, ATG7 knock-down cells appeared to be more differentiated compared to the control (scrambled shRNA). Our findings suggest a role for basal autophagy in the survival, differentiation decisions and clonogenicity of CML cells, and support the combined use of autophagy inhibition with TKIs for the eradication of CML stem/progenitor cells. This could be partially attributed to a bypass of the differentiation block upon autophagy inhibition, which facilitates TKI-targeting. We underline the necessity for the development of specific autophagy inhibitors that in combination with TKIs could potentially eradicate the fraction of persistent CML stem/progenitor cells and offer a curative option for CML patients.","abstract_has_math":false,"creators":["Karvela, Maria"],"institution":"University of Glasgow","degree_name":null,"degree_level":"PhD","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-11-19T08:22:51Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://theses.gla.ac.uk/4271/7/2013KarvelaPhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://theses.gla.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Atheses.gla.ac.uk%3A4271","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Karvela, Maria"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Glasgow"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://theses.gla.ac.uk/4271/"]},{"key":"dc:relation.isreferencedby.uri","label":"Dc Relation Isreferencedby URI","values":["https://gla.on.worldcat.org/oclc/872414759"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["PhD"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://theses.gla.ac.uk/4271/7/2013KarvelaPhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukemia (CML), however, fail to cure the disease due to the persistence of a refractory fraction of stem/progenitor cells. Autophagy is a recycling mechanism utilised by the cell as a survival mechanism under stressful conditions, and its induction has been suggested to have a cytoprotective role in cancer cells. In this study we demonstrate that autophagy is triggered in CML upon TKI-mediated inhibition of BCR-ABL, and protects from cell death. In order to evaluate if specific autophagy inhibition enhances TKI effects, we stably transduced primary CML stem/progenitor cells with a vector carrying a short-hairpin against the key autophagy gene ATG7. Knock-down of basal ATG7/autophagy levels in CML stem/progenitor cells inhibited by approximately 50% the survival of the cells in a clonogenic assay, and reduced by 75% their erythroid differentiation potential. Furthermore, ATG7 knock-down enhanced the effects of TKIs imatinib (IM; 1st), dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without TKI treatment, did not have a significant effect on survival and proliferation. ATG7 was also knocked-down in final disease stage, blast crisis (BC), patient-derived K562 and KCL22 cell lines. Both cell lines appeared to depend significantly on autophagy for survival as indicated by high apoptosis levels (70-100%) after ATG7 knock-down. Interestingly, ATG7 knock-down cells appeared to be more differentiated compared to the control (scrambled shRNA). Our findings suggest a role for basal autophagy in the survival, differentiation decisions and clonogenicity of CML cells, and support the combined use of autophagy inhibition with TKIs for the eradication of CML stem/progenitor cells. This could be partially attributed to a bypass of the differentiation block upon autophagy inhibition, which facilitates TKI-targeting. We underline the necessity for the development of specific autophagy inhibitors that in combination with TKIs could potentially eradicate the fraction of persistent CML stem/progenitor cells and offer a curative option for CML patients."]},{"key":"dc:format","label":"Dc Format","values":["pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Investigation of autophagy as a survival factor for chronic myeloid leukaemia"]}]}],"canonical_facts":{"dc:creator":["Karvela, Maria"],"dc:date":["2013"],"dc:date.issued":["2013"],"dc:description.abstract":["Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of chronic myeloid leukemia (CML), however, fail to cure the disease due to the persistence of a refractory fraction of stem/progenitor cells. Autophagy is a recycling mechanism utilised by the cell as a survival mechanism under stressful conditions, and its induction has been suggested to have a cytoprotective role in cancer cells. In this study we demonstrate that autophagy is triggered in CML upon TKI-mediated inhibition of BCR-ABL, and protects from cell death. In order to evaluate if specific autophagy inhibition enhances TKI effects, we stably transduced primary CML stem/progenitor cells with a vector carrying a short-hairpin against the key autophagy gene ATG7. Knock-down of basal ATG7/autophagy levels in CML stem/progenitor cells inhibited by approximately 50% the survival of the cells in a clonogenic assay, and reduced by 75% their erythroid differentiation potential. Furthermore, ATG7 knock-down enhanced the effects of TKIs imatinib (IM; 1st), dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without TKI treatment, did not have a significant effect on survival and proliferation. ATG7 was also knocked-down in final disease stage, blast crisis (BC), patient-derived K562 and KCL22 cell lines. Both cell lines appeared to depend significantly on autophagy for survival as indicated by high apoptosis levels (70-100%) after ATG7 knock-down. Interestingly, ATG7 knock-down cells appeared to be more differentiated compared to the control (scrambled shRNA). Our findings suggest a role for basal autophagy in the survival, differentiation decisions and clonogenicity of CML cells, and support the combined use of autophagy inhibition with TKIs for the eradication of CML stem/progenitor cells. This could be partially attributed to a bypass of the differentiation block upon autophagy inhibition, which facilitates TKI-targeting. We underline the necessity for the development of specific autophagy inhibitors that in combination with TKIs could potentially eradicate the fraction of persistent CML stem/progenitor cells and offer a curative option for CML patients."],"dc:format":["pdf"],"dc:identifier.uri":["https://theses.gla.ac.uk/4271/7/2013KarvelaPhD.pdf"],"dc:language":["en"],"dc:publisher.institution":["University of Glasgow"],"dc:relation.isreferencedby":["https://theses.gla.ac.uk/4271/"],"dc:relation.isreferencedby.uri":["https://gla.on.worldcat.org/oclc/872414759"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public"],"dc:title":["Investigation of autophagy as a survival factor for chronic myeloid leukaemia"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["PhD"]},"updated_at":"2026-11-19T08:22:51Z"}